These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30580579)

  • 1. Visualization of Blood Glucose Fluctuations Using Continuous Glucose Monitoring in Patients Undergoing Hemodialysis.
    Mori K; Emoto M; Abe M; Inaba M
    J Diabetes Sci Technol; 2019 Mar; 13(2):413-414. PubMed ID: 30580579
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
    Dieuzeide G; Chuang LM; Almaghamsi A; Zilov A; Chen JW; Lavalle-González FJ
    Prim Care Diabetes; 2014 Jul; 8(2):111-7. PubMed ID: 23953707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections.
    Li FF; Fu LY; Zhang WL; Su XF; Wu JD; Sun J; Ye L; Ma JH
    J Diabetes Res; 2016; 2016():1028945. PubMed ID: 26839889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SimpleMix study with biphasic insulin aspart 30: a randomized controlled trial investigating patient-driven titration versus investigator-driven titration.
    Gao Y; Luquez C; Lynggaard H; Andersen H; Saboo B
    Curr Med Res Opin; 2014 Dec; 30(12):2483-92. PubMed ID: 25180608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study.
    Lezzar A; Ayad F; Dahaoui A; Salah-Mansour A; Berrouiguet AY
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S37-44. PubMed ID: 23958570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S; Sothiratnam R; Sari R; Andersen H; Hiort LC; Rao P
    Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HONE IN ON THE RANGE.
    Scheiner G
    Diabetes Self Manag; 2015; 32(4):18-20, 23. PubMed ID: 26380396
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
    Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
    Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.
    Malek R; Arbouche Z; Bachaoui M; Zinai S; Dahaoui A; Senoussaoui S; Salah-Mansour A
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S45-9. PubMed ID: 23958572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P; Wojciechowski P; Siejka S; Małecki P; Hak L; Malecki MT
    Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subject-driven titration of biphasic insulin aspart 30 twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial.
    Yang W; Zhu L; Meng B; Liu Y; Wang W; Ye S; Sun L; Miao H; Guo L; Wang Z; Lv X; Li Q; Ji Q; Zhao W; Yang G
    J Diabetes Investig; 2016 Jan; 7(1):85-93. PubMed ID: 26816605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.
    Chen L; Xing X; Lei M; Liu J; Shi Y; Li P; Qin G; Li C; Li Y; Wang Q; Gao T; Hu L; Wang Y; Yang W
    Chin Med J (Engl); 2014; 127(2):208-12. PubMed ID: 24438605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Algorithm Dedicated to Blood Glucose Monitoring in Insulin-Treated Elderly Dependent People With Diabetes.
    Grino M; Loundou A; Boucekine M; Alitta Q; Oliver C
    J Diabetes Sci Technol; 2019 Mar; 13(2):410-412. PubMed ID: 30537870
    [No Abstract]   [Full Text] [Related]  

  • 15. Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis.
    Gallieni M; De Salvo C; Lunati ME; Rossi A; D'Addio F; Pastore I; Sabiu G; Miglio R; Zuccotti GV; Fiorina P
    Acta Diabetol; 2021 Aug; 58(8):975-981. PubMed ID: 33743082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some specificities in the management of hyperglycemia in patients with diabetic kidney disease.
    Dragović T; Marinković D; Kiković S; Pejović J; Hajduković Z
    Vojnosanit Pregl; 2016 Sep; 73(9):857-63. PubMed ID: 29320619
    [No Abstract]   [Full Text] [Related]  

  • 17. Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results.
    Nobels F; D'Hooge D; Crenier L
    Curr Med Res Opin; 2012 Jun; 28(6):1017-26. PubMed ID: 22612579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of postprandial glucose: Recommended targets and treatment with biphasic insulin.
    Liebl A
    Prim Care Diabetes; 2016 Dec; 10(6):391-397. PubMed ID: 27427307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.